
News|Articles|March 1, 2011
FDA Pipeline Preview, March 2011 (Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib)
Recent FDA action (through, February 2011) related to Contrave, rabeprazole sodium extended-release capsules, Avodart, Mu Delta, Carfilzomib, Vascugel, INX-0818, vosaroxin, Acurox, fidaxomicin, melanoma cancer vaccine, NSI-566RSC, Regorafenib.
Advertisement
Complete response
Fast-track designation
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Cobenfy in Practice: Hope, Hurdles, and the Next Chapter in Schizophrenia Care
2
Eylea HD Provides Vision Gains and Longer Dosing Intervals in Real-World Analysis | AAO 2025
3
What’s New in the Diagnosis and Treatment of Headaches That Ophthalmologists Should Know About? | AAO 2025
4
Making Sense of the Eye Pain-Headache Connection | AAO 2025
5